ClinicalTrials.gg
CompletedNCT00773747Updated Apr 30, 2021Results posted

Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)

A Phase 3 interventional study of Vorinostat and bortezomib in Multiple Myeloma, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-30.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
637
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing vorinostat in Multiple Myeloma — none open to participants now, 1 under way, none of them phase 3. Vorinostat · Multiple Myeloma.

Enrollment
Largest of 17
637 · median 31
Started
2008
with 4 others
Phase 3
Only one
of the 19
Registered
9th of 19
by date
Lead sponsor
6 of 19
Merck Sharp & Dohme LLC

Among the 19 studies testing vorinostat in Multiple Myeloma, this one has the largest enrollment of the 17 interventional ones that give a count, is one of 5 that started in 2008, is the only one in phase 3, and was the 9th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

None of the 19 studies testing vorinostat in Multiple Myeloma is open now. The open studies under Multiple Myeloma, anywhere →

Where they have run

About vorinostat

Vorinostat: first FDA approval 2006 (ZOLINZA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing vorinostat in Multiple Myeloma as a file.
02

Study summary

Study of the efficacy and safety of bortezomib administered in combination with vorinostat in patients with relapsed or refractory multiple myeloma. Histone deacetylases (HDAC) facilitate gene transcription by modulating the uncoiling of chromatin. HDAC function is dysregulated in hematologic and solid malignancies, and this dysregulation may result in over-expression of oncogenes. Thus, inhibition of HDACs may result in anti-cancer effects. HDAC inhibitors, like vorinostat, represent a new class of antitumor agents that have the ability to induce antiproliferative effects including cyto-differentiation, cell cycle growth arrest or apoptosis in various cancer cell lines. Several studies have investigated the in vitro antimyeloma activity of vorinostat in combination with bortezomib and have demonstrated that vorinostat may act synergistically with bortezomib to modulate tumor cell growth. Mitsiades et al have shown that vorinostat enhances the sensitivity of bortezomib. Pei et al found that exposure of human multiple myeloma cell lines \& patient-derived multiple myeloma cells to bortezomib and vorinostat resulted in synergistic interactions as a result of: (1) Interruption of NF-kB \& related signaling pathways (JNK, XIAP, Mcl-1, etc.) (2) Inhibition of Hsp90 (3)Induction of ER stress signal and (4) acetylation of Dynein/disruption of aggresome function/formation, salvage for ubiquitinated proteins. In addition a marked increase in mitochondrial injury, caspase activation, and apoptosis was also observed. Bortezomib is indicated for the treatment of patients with multiple myeloma. Two Phase I dose-ranging studies of a regimen combining vorinostat and bortezomib among patients with relapsed as well asend-stage, refractory multiple myeloma have been conducted. These studies enrolled a total of 57 patients. In these studies, administration of vorinostat with standard doses of bortezomib resulted in responses in 20/45 (44%) evaluable patients (Weber et al 2007, Badros et al 2007). The purpose of the present study is to definitively evaluate the clinical activity of vorinostat in combination with bortezomib inpatients with multiple myeloma.

03

Conditions studied

  • Multiple Myeloma

Keywords

  • Neoplasms, Plasma Cell
  • Neoplasms by Histologic Type
  • Neoplasms
  • Hemostatic Disorders
  • Vascular Diseases
  • Cardiovascular Diseases
  • Paraproteinemias
  • Blood Protein Disorders
  • Hematologic Diseases
  • Hemorrhagic Disorders
  • Lymphoproliferative Disorders
  • Immunoproliferative Disorders
  • Immune System Diseases
  • Vorinostat
  • Bortezomib
  • Anti-Inflammatory Agents, Non-Steroidal
  • Analgesics, Non-Narcotic
  • Analgesics
  • Sensory System Agents
  • Peripheral Nervous System Agents
  • Physiological Effects of Drugs
  • Pharmacologic Actions
  • Anti-Inflammatory Agents
  • Therapeutic Uses
  • Antirheumatic Agents
  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Molecular Mechanisms of Pharmacological Action
  • Anticarcinogenic Agents
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has an established diagnosis of multiple myeloma based on the myeloma diagnostic criteria.
  • Participant has received at least 1 but not more than 3 prior anti-myeloma regimens and has progressive disease after the most recent treatment regimen.
  • Participant must have adequate organ function.

Exclusion criteria

Exclusion criteria:

  • Participant has had a prior bone marrow transplant or plans to undergo any type of bone marrow transplantation within 4 weeks of the initiation of study therapy.
  • Participant has known to any components of bortezomib or vorinostat.
  • Participant has active or C, plasma cell leukemia, or is (HIV) positive.
  • Participant has had prior treatment with vorinostat or histone deacetylase (HDAC) inhibitors.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
637 participants (actual)

Study arms

  • Experimental
    Vorinostat + Bortezomib

    Participants will receive vorinostat four 100 mg capsules (400 mg total) orally 0-30 minutes after a meal on Days 1-14 of a 21-day treatment cycle and bortezomib 1.3 mg/m\^2 by intravenous injection on Days 1, 4, 8, and 11 of a 21-day treatment cycle.

    Drug: Vorinostat · Drug: bortezomib

  • Placebo comparator
    Placebo + Bortezomib

    Participants will receive four placebo capsules orally 0-30 minutes after a meal on Days 1-14 of a 21-day treatment cycle and bortezomib 1.3 mg/m\^2 by intravenous injection on Days 1, 4, 8, and 11 of a 21-day treatment cycle.

    Drug: bortezomib · Drug: placebo to vorinostat

Interventions

  • Four 100 mg capsules vorinostat taken orally, once daily, on Days 1 through 14 of each 21-day treatment cycle.

    Also known as: Zolinza

  • 1.3 mg/m2 of bortezomib by IV push, on Days 1, 4, 8, and 11 of each 21-day treatment cycle.

    Also known as: Velcade

  • Drugplacebo to vorinostat

    Four placebo capsules taken orally, once daily, on Days 1 through 14 of each 21-day treatment cycle.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    Progression-free survival was measured from the start of the treatment to the time when the criteria for progression was met or death due to any cause (whichever is first recorded). Response to study therapy was assessed using European Blood and Marrow Transplantation Group (EBMT) Criteria. A stratified Cox proportional hazards model was used with Efron's likelihood approximation to account for ties in event times.

    Time frame: From randomization to event of disease progression or death assessed up to 32 months (final study analysis)

Secondary outcomes

  1. Number of Participants With Grade 3-5 Clinical or Laboratory Adverse Events (AEs)

    An adverse event (AE) was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product/protocol-specified procedure, whether or not considered related to the medicinal product/protocol-specified procedure. Any worsening of a preexisting condition temporally associated with the use of the product was also an AE. Grades come from the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Per protocol, clinical and laboratory AEs are presented as a combined total for each grade.

    Time frame: Up to 722 days

  2. Overall Survival

    Overall survival was measured from the start of the treatment to death due to any cause. Overall Survival is represented as the number of deaths per 100-person- months and was computed by dividing the number of participants with an event of death that occurred during the study follow-up period by the total duration of follow-up (in 100 months) for all the participants in each cohort since participants had different lengths of follow-up.

    Time frame: From randomization up to 32 months (final study analysis)

  3. Time to Progression

    Time to progression was measured from the start of the treatment to the time when the criteria for progression was met or death due to myeloma (whichever is first recorded). Response to study therapy was assessed using European Blood and Marrow Transplantation Group (EBMT) Criteria. A stratified Cox proportional hazards model was used with Efron's likelihood approximation to account for ties in event times.

    Time frame: Baseline and at the end of each 21-day Cycle assessed up to 32 months (final study analysis)

  4. Objective Response Rate

    Objective response rate was measured as the proportion of patients who achieved a confirmed partial response or better during the course of the study. Response to study therapy was assessed using EBMT Criteria and confirmed by Independent Adjudication Review.

    Time frame: Baseline and at the end of each 21-day Cycle assessed up to 32 months (final study analysis)

07

Results

Posted Apr 30, 2021

Participant flow

This study enrolled participants with an established diagnosis of multiple myeloma based on standard criteria that have received at least 1 but not more than 3 prior anti-myeloma regimens and have demonstrated progressive disease after the most recent treatment regimen. Additional inclusion and exclusion criteria applied.

Participant flow — Overall Study
MilestoneVorinostat + BortezomibPlacebo + Bortezomib
Started317320
Treated315320
Completed2024
Not completed297296
Withdrew: Lack of efficacy112144
Withdrew: Physician decision2618
Withdrew: Lost to follow-up01
Withdrew: Protocol violation22
Withdrew: Withdrawal by subject8961
Withdrew: Adverse event6162
Withdrew: Death58
Withdrew: Not treated20

Outcome measures

PrimaryProgression-Free Survival (PFS)

Progression-free survival was measured from the start of the treatment to the time when the criteria for progression was met or death due to any cause (whichever is first recorded). Response to study therapy was assessed using European Blood and Marrow Transplantation Group (EBMT) Criteria. A stratified Cox proportional hazards model was used with Efron's likelihood approximation to account for ties in event times.

Time frame:
From randomization to event of disease progression or death assessed up to 32 months (final study analysis)
Reported as:
Median · Months
Progression-Free Survival (PFS)
MonthsVorinostat + BortezomibPlacebo + Bortezomib
Progression-Free Survival (PFS)7.63 ± 6.876.83 ± 5.67
Statistical analysis
  • Vorinostat + Bortezomib vs Placebo + Bortezomib · Regression, Cox · p = = 0.0100 · Cox proportional hazard: 0.774 · 95% CI 0.636 to 0.941
SecondaryNumber of Participants With Grade 3-5 Clinical or Laboratory Adverse Events (AEs)

An adverse event (AE) was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product/protocol-specified procedure, whether or not considered related to the medicinal product/protocol-specified procedure. Any worsening of a preexisting condition temporally associated with the use of the product was also an AE. Grades come from the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Per protocol, clinical and laboratory AEs are presented as a combined total for each grade.

Time frame:
Up to 722 days
Reported as:
Count of participants · Participants
Number of Participants With Grade 3-5 Clinical or Laboratory Adverse Events (AEs)
ParticipantsVorinostat + BortezomibPlacebo + Bortezomib
Grade 3272240
Grade 410885
Grade 51117
SecondaryOverall Survival

Overall survival was measured from the start of the treatment to death due to any cause. Overall Survival is represented as the number of deaths per 100-person- months and was computed by dividing the number of participants with an event of death that occurred during the study follow-up period by the total duration of follow-up (in 100 months) for all the participants in each cohort since participants had different lengths of follow-up.

Time frame:
From randomization up to 32 months (final study analysis)
Reported as:
Number · Events/100-person Months
Overall Survival
Events/100-person MonthsVorinostat + BortezomibPlacebo + Bortezomib
Overall Survival1.7 ± 1.561.9 ± 1.75
Statistical analysis
  • Vorinostat + Bortezomib vs Placebo + Bortezomib · Regression, Cox · p = 0.3496 · Cox proportional hazard: 0.858 · 95% CI 0.622 to 1.184
SecondaryTime to Progression

Time to progression was measured from the start of the treatment to the time when the criteria for progression was met or death due to myeloma (whichever is first recorded). Response to study therapy was assessed using European Blood and Marrow Transplantation Group (EBMT) Criteria. A stratified Cox proportional hazards model was used with Efron's likelihood approximation to account for ties in event times.

Time frame:
Baseline and at the end of each 21-day Cycle assessed up to 32 months (final study analysis)
Reported as:
Median · Months
Time to Progression
MonthsVorinostat + BortezomibPlacebo + Bortezomib
Time to Progression7.73 ± 7.007.03 ± 6.33
SecondaryObjective Response Rate

Objective response rate was measured as the proportion of patients who achieved a confirmed partial response or better during the course of the study. Response to study therapy was assessed using EBMT Criteria and confirmed by Independent Adjudication Review.

Time frame:
Baseline and at the end of each 21-day Cycle assessed up to 32 months (final study analysis)
Reported as:
Number · Percentage of Participants
Objective Response Rate
Percentage of ParticipantsVorinostat + BortezomibPlacebo + Bortezomib
Objective Response Rate56.2 ± 50.540.6 ± 35.2

Adverse events

Collected over Up to 722 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vorinostat + Bortezomib—130/315 (41.3%)312/315 (99%)
Placebo + Bortezomib—138/320 (43.1%)306/320 (95.6%)
Most frequent serious events
Showing 10 of 160
Most frequent serious events
EventVorinostat + BortezomibPlacebo + Bortezomib
Accidental overdoseInjury, poisoning and procedural complications32/31527/320
PneumoniaInfections and infestations14/31513/320
Neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)10/31513/320
DiarrhoeaGastrointestinal disorders9/31510/320
ThrombocytopeniaBlood and lymphatic system disorders9/3153/320
PyrexiaGeneral disorders6/3159/320
VomitingGastrointestinal disorders8/3157/320
GastroenteritisInfections and infestations6/3150/320
Herpes zosterInfections and infestations0/3156/320
FatigueGeneral disorders3/3155/320
Most frequent other events
Showing 10 of 44
Most frequent other events
EventVorinostat + BortezomibPlacebo + Bortezomib
DiarrhoeaGastrointestinal disorders194/315133/320
NauseaGastrointestinal disorders193/315126/320
ThrombocytopeniaBlood and lymphatic system disorders172/315106/320
VomitingGastrointestinal disorders140/31580/320
FatigueGeneral disorders125/31596/320
NeutropeniaBlood and lymphatic system disorders112/31595/320
AnaemiaBlood and lymphatic system disorders91/31579/320
ConstipationGastrointestinal disorders64/31586/320
NeuralgiaNervous system disorders82/31586/320
Decreased appetiteMetabolism and nutrition disorders75/31585/320

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Vorinostat + BortezomibPlacebo + BortezomibTotal
Mean60.9 ± 10.062.7 ± 10.061.8 ± 10.0
Age, Customized
Age, Customized(Participants)Vorinostat + BortezomibPlacebo + BortezomibTotal
In utero000
Preterm newborn infants (gestational age < 37 wks)000
Newborns (0-27 days)000
Infants and toddlers (28 days-23 months)000
Children (2-11 years)000
Adolescents (12-17 years)000
Adults (18-64 years)200181381
From 65-84 years116137253
85 years and over123
Sex: Female, Male
Sex: Female, Male(Participants)Vorinostat + BortezomibPlacebo + BortezomibTotal
Female126134260
Male191186377
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Vorinostat + BortezomibPlacebo + BortezomibTotal
Hispanic or Latino322355
Not Hispanic or Latino285297582
Unknown or Not Reported000
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Dimopoulos M, Siegel DS, Lonial S, Qi J, Hajek R, Facon T, Rosinol L, Williams C, Blacklock H, Goldschmidt H, Hungria V, Spencer A, Palumbo A, Graef T, Eid JE, Houp J, Sun L, Vuocolo S, Anderson KC. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol. 2013 Oct;14(11):1129-1140. doi: 10.1016/S1470-2045(13)70398-X. Epub 2013 Sep 19. PubMed 24055414 ↗

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2008 to primary completion in Sep 2011, 33 months.

Results were first posted in Apr 2021, 9 years 7 months after primary completion.

Of 107 industry-sponsored phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 66. This study's 33 months is below that.

Counting every sponsor, half of 179 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2008
First posted
Oct 16, 2008
StartActual
Dec 1, 2008
Primary completionActual
Sep 8, 2011
CompletionActual
Jun 30, 2015
Results first posted
Apr 30, 2021
Last update
Apr 30, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00773747
Responsible party
Sponsor
First posted
Oct 16, 2008
Start date
Dec 1, 2008
Primary completion
Sep 8, 2011
Completion
Jun 30, 2015
Results posted
Apr 30, 2021
Last update
Apr 30, 2021

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vorinostat

Start the discussion